A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis
| Status: | Recruiting |
|---|---|
| Conditions: | Psoriasis |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 1/27/2019 |
| Start Date: | November 20, 2018 |
| End Date: | December 2019 |
| Contact: | Cherie Robbins, BScN |
| Email: | clinicaltrialsinfo@anaptysbio.com |
| Phone: | 858-362-6295 |
A Phase II, Randomized, Placebo-controlled, Double-blind, Multiple Dose Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis
A study to evaluate the efficacy and safety, and pharmacokinetic (PK) profile of multiple
doses of ANB019 in subjects with Palmoplantar Pustulosis (PPP)
doses of ANB019 in subjects with Palmoplantar Pustulosis (PPP)
This study is a Phase II, randomized, placebo-controlled, double-blind, multiple dose study
to evaluate the efficacy and safety, and PK of ANB019 in subjects with Palmoplantar
Pustulosis
to evaluate the efficacy and safety, and PK of ANB019 in subjects with Palmoplantar
Pustulosis
Inclusion Criteria:
- Clinically confirmed diagnosis of PPP
- Disease duration of at least 6 months prior to screening
- Present with active pustules on palms or/and soles at screening
Exclusion Criteria:
- Any other ongoing inflammatory disease that interfere with the investigator's ability
to evaluate the subject's response to therapy
- History of recurrent or active/serious infection
- Ongoing use of psoriasis prohibited medication
Other protocol-defined inclusion/exclusion criteria may apply
We found this trial at
2
sites
Click here to add this to my saved trials
Click here to add this to my saved trials